Dyadic International, Inc. Extends Collaboration With The Scripps Research Institute

JUPITER, Fla., Dec. 14 /PRNewswire-FirstCall/ -- Dyadic International, Inc. ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").

Since the initial annotation project, the genomic and computational tools available to Scripps and Dyadic have improved. During this time, Dyadic has also re-sequenced its C1 genome which has provided greater knowledge of this novel organism. Lastly, the worldwide scientific community has been very active over the last few years in sequencing the genomes of a multitude of living organisms. Together, these advances now provide the impetus for Dyadic to further improve the productivity and efficiency of its patented and proprietary C1 Platform Technology by re-annotating the C1 genome and leveraging the most current scientific data. Dyadic intends to use this research to continue developing and manufacturing enzyme products for the bioenergy, food and feed, pulp and paper, and textile markets while also leveraging its technologies for use in the biopharmaceutical, cosmetic and nutraceutical industries.

Mark Emalfarb, Dyadic's CEO, stated, "The re-annotated C1 genome developed with Scripps Florida will provide Dyadic and its commercial partners with a more accurate blueprint of the C1 fungal strain which serves as the primary engine for Dyadic's growth. This research will help Dyadic make greater quantities of more efficient enzymes and proteins at lower costs to help provide solutions to problems facing the world such as using cellulosic ethanol to help reduce our dependence on foreign oil. In the biopharmaceutical industry, we intend to further utilize our technologies to help develop antibodies and other therapeutic proteins in a shorter time, at larger volumes and at lower costs. This collaboration also further underscores the strong relationship between Dyadic and Scripps as well as Dyadic's continued commitment to the development of a successful biotechnology cluster in South Florida."

About Scripps

Scripps Florida--a division of Scripps--is a 350,000 square-foot, state-of-the-art biomedical research facility on 100 acres adjacent to the Florida Atlantic University campus located in Jupiter, Florida in Palm Beach County. Nearly 300 faculty members, scientific, technical and administrative staff currently work at this facility focusing on basic biomedical science, drug discovery, and technology development. Please visit the Scripps Florida website at www.scripps.edu/florida.

Dyadic is an early-stage biotechnology company headquartered in Jupiter, Florida that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic also utilizes the C1 Platform Technology, an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic aggressively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Dyadic International, Inc.